SCHEMBL14320321

SCHEMBL14320321

CN(C(=O)c1ccc(N)cc1)C1CC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
GAA P10253 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
POLB P06746 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
PDK2 Q15119 3/20 0.44
FASN P49327 1/20 0.43
SYK P43405 1/20 0.43
HPGD P15428 2/20 0.42
USP30 Q70CQ3 1/20 0.42
CCR5 P51681 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13735411 0.95 ALDH1A1 (0.54) ALDH1A1GAASMN1; SMN2L3MBTL1POLB
SCHEMBL14096734 0.93 ALDH1A1 (0.44) ALDH1A1GAASMN1; SMN2L3MBTL1POLB
SCHEMBL3455371 0.91 ALDH1A1 (0.58) ALDH1A1GAASMN1; SMN2POLBNPC1
SCHEMBL7368693 0.89 NPC1 (0.47) ALDH1A1GAASMN1; SMN2L3MBTL1POLB
SCHEMBL1164100 0.87 MCHR1 (0.50) ALDH1A1L3MBTL1LMNAMAPTPDK2
SCHEMBL16907559 0.83 PDK2 (0.58) ALDH1A1GAASMN1; SMN2L3MBTL1POLB
SCHEMBL15976796 0.81 ALDH1A1 (0.48) ALDH1A1GAASMN1; SMN2L3MBTL1POLB
SCHEMBL21590246 0.81 ALDH1A1 (0.48) ALDH1A1GAASMN1; SMN2L3MBTL1POLB
SCHEMBL3840449 0.81 CCR3 (0.51) ALDH1A1GAASMN1; SMN2L3MBTL1PDK2
SCHEMBL9001749 0.81 CCR3 (0.51) ALDH1A1GAASMN1; SMN2L3MBTL1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 US disclosed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 US disclosed
US-9499535-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2016-11-22 US disclosed
EP-2699572-B1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2016-08-10 EP disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 US disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
CN-103492389-A Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors ORIGENIS GMBH 2014-01-01 CN disclosed
US-20120329785-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK ALDH1A1 4333/4885GAA 742/4885SMN1; SMN2 882/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK ALDH1A1 3674/4885GAA 940/4885SMN1; SMN2 835/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK ALDH1A1 4333/4885GAA 742/4885SMN1; SMN2 882/4885
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK ALDH1A1 4333/4885GAA 742/4885SMN1; SMN2 882/4885
US-20120329785-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK3 ALDH1A1 4394/4885GAA 499/4885SMN1; SMN2 609/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK ALDH1A1 4184/4885GAA 698/4885SMN1; SMN2 986/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK ALDH1A1 4184/4885GAA 698/4885SMN1; SMN2 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.